Role of xenobiotic efflux transporters in resistance to vincristine

Biomedicine and Pharmacotherapy

Volumn 62, Issue 2, 2008, Pages 59-64

  Huang, Rong S ^a   Murry, Daryl J ^b   Foster, David R ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

MDR1; Multidrug resistance associated proteins; P glycoprotein; Transporters; Vincristine

Indexed keywords

GLYCOPROTEIN P; LY 3359979; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; UNCLASSIFIED DRUG; VINCRISTINE; XENOBIOTIC AGENT; ZOSUQUIDAR;

ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG PENETRATION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MONOLAYER CULTURE; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; XENOBIOTIC METABOLISM; XENOBIOTIC STRESS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELL LINE, TUMOR; CELL SURVIVAL; DIBENZOCYCLOHEPTENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PERMEABILITY; QUINOLINES; VINCRISTINE;

EID: 38949113151     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.04.011     Document Type: Article

References (22)

1. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
2. Kool M., de Haas M., and Scheffer G.L. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57 (1997) 3537-3547
3. Minemura M., Tanimura H., and Tabor E. Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol 15 (1999) 559-563
4. Young L.C., Campling B.G., Cole S.P.C., Deeley R.G., and Gerlach J.H. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7 (2001) 1798-1804
5. Ferguson R.E., Jackson S.M., and Stanley A.J. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer 115 (2005) 155-163
6. van Tellingen O., Buckle T., Jonker J., Mvd V., and Beijnen J. P-glycoprotein and mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo. Br J Cancer 89 (2003) 1776-1782
7. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92 (2000) 1295-1302
8. Gruol D.J., King M.N., and Kuehne M.E. Evidence for the locations of distinct steroid and vinca alkaloid interaction domains within the murine mdr1b p-glycoprotein. Mol Pharmacol 62 (2002) 1238-1248
9. Van Aubel R.A.M.H., Koenderink J.B., Peters J.G.P., Van Os C.H., and Russel F.G.M. Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. Mol Pharmacol 56 (1999) 714-719
10. Huang R., Murry D.J., Kolwankar D., Hall S.D., and Foster D.R. Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol 71 (2006) 1695-1704
11. Irvine J., Takahashi L., Lockhart K., Cheong J., Tolan J.W., Selick H.E., et al. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88 (1999) 28-33
12. Karyekar C.S., Eddington N.D., Garimella T.S., Gubbins P.O., and Dowling T.C. Evaluation of P-glycoprotein-mediated renal drug interaction in an MDR1-MDCK model. Pharmacotherapy 23 (2003) 436-442
13. Guo A., Marinaro W., Hu P., and Sinko P.J. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 30 (2002) 457-463
14. Luo F.R., Paranjpe P.V., Guo A., Rubin E., and Sinko P. Intestinal transport of irinotecan in Caco2 cells and MDCKII cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos 30 (2002) 763-770
15. Luqmani Y.A. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14 (2005) 35-48
16. McLeod H. Clinical reversal of the multidrug resistance phenotype: true tumor modulation or pharmacokinetic interaction?. Eur J Cancer 14 (1994) 2039-2041
17. Bauer K.S., Karp J.E., Garimella T.S., Wu S., Tan M., and Ross D.D. A phase I and pharmacologic study of idarubicin, cytarabin, etoposide and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. Leuk Res 29 (2005) 263-271
18. Chauncey T.R. Drug resistance mechanisms in acute leukemia. Curr Opin Oncol 13 (2001) 21-26
19. Bahr O., Rieger J., Duffner F., Meyemann R., Weller M., and Wick W. P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell. Brain Pathol 13 (2003) 482-494
20. Pichler A., Zelcer N., Prior J.L., Kuil A.J., and Piwinca-Worms D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 11 (2005) 4487-4494
21. Cui Y., Konig J., Buchholz U., Spring H., Leier I., and Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55 (1999) 929-937
22. Koike K., Kawabe T., Tanaka T., Toh S., Uchiumi T., Wada M., et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 57 (1997) 5475-5479